• Myeloid S100A8/A9 Regulates Cardiac Hypertrophy to Heart Fai

  2026-04-28

  This study uses single-cell RNA sequencing to reveal that myeloid-derived S100A8/A9 is a central regulator of the transition from adaptive cardiac hypertrophy to heart failure after pressure overload. The findings clarify immune cell-specific signaling and identify S100A8/A9 as a therapeutic target, offering new mechanistic insights for cardiovascular research.

• Blocking Extracellular Vesicle Release in Triple-Negative Br

  2026-04-27

  McNamee et al. present an extensive analysis of how pharmacological inhibitors, including Calpeptin, suppress the release of extracellular vesicles (EVs) from triple-negative breast cancer (TNBC) cells. Their work clarifies the contribution of EVs to cancer aggressiveness and evaluates the efficacy of multiple inhibitors in modulating cell-to-cell communication, with key implications for therapeutic targeting and EV-based research.

• Chloroquine Diphosphate: Autophagy Modulation in Cancer Rese

  2026-04-27

  Explore how Chloroquine Diphosphate (4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid) reshapes cancer research through autophagy modulation, TLR7/9 inhibition, and therapeutic sensitization. This thought-leadership article bridges mechanistic insight with actionable guidance for translational scientists, critically synthesizing evidence—including recent discoveries in immune-autophagy crosstalk—to inform next-generation experimental designs and clinical strategies.

• 17-AAG (Tanespimycin): HSP90 Inhibitor Benchmarks & Protocol

  2026-04-26

  17-AAG (Tanespimycin) is a potent HSP90 chaperone inhibitor with nanomolar activity in cancer models. Supplied by APExBIO, it demonstrates robust, selective client protein degradation and reproducible antitumor efficacy. This dossier details its mechanism, benchmarks, and optimal research integration.

• Translating Hypoxia Pathway Insights: YC-1 for Cancer Biolog

  2026-04-25

  This thought-leadership article explores the mechanistic and translational impact of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol in modulating hypoxia-inducible signaling and tumor angiogenesis. Bridging evidence from foundational protocols and recent advances, it provides strategic guidance for translational researchers aiming to integrate APExBIO's YC-1 into robust cancer and vascular biology research workflows.

• Improving In Vitro Evaluation of Cancer Drug Responses: Insi

  2026-04-24

  Schwartz et al.'s dissertation provides a systematic analysis of how in vitro assays evaluate anti-cancer drug responses, highlighting how the metrics of relative viability and fractional viability capture distinct aspects of cell proliferation and death. The work clarifies methodological ambiguities in drug sensitivity assessment and offers improved experimental strategies for cancer research.

• Vorinostat (SAHA): Precision Epigenetic Modulation Beyond On

  2026-04-24

  Explore how Vorinostat (suberoylanilide hydroxamic acid) enables advanced epigenetic research, bridging cancer biology with innovative assay strategies. This cornerstone guide reveals practical insights, protocol parameters, and translational perspectives not found in standard reviews.

• TRPV1 Modulation Alters Immune Response in Metastatic Breast

  2026-04-23

  This study investigates how modulating TRPV1 channels affects immune cell cytokine secretion in mice bearing metastatic breast carcinoma. The findings reveal that TRPV1 activation has context-dependent effects on inflammatory and cytotoxic responses, raising important considerations for the therapeutic use of TRPV1 agonists in cancer models.

• Ethacridine Lactate Monohydrate: Antiseptic Strategy for Epi

  2026-04-23

  This article synthesizes mechanistic, strategic, and translational insights on Ethacridine lactate monohydrate (7-ethoxyacridine-3,9-diamine) as a precision antiseptic agent. Bridging data from super-enhancer network research and recent workflow innovations, it offers actionable guidance for translational scientists seeking high-fidelity microbial control in advanced stem cell and chromatin assays.

• Topotecan as First-Line Therapy in Small Cell Lung Cancer: I

  2026-04-22

  This review examines the innovation, findings, and methodology of Stewart's pivotal study on the use of topotecan as a first-line treatment in small cell lung cancer (SCLC). The paper's rigorous evaluation of topotecan-based regimens highlights the potential for effective, manageable alternatives to traditional therapies, with important implications for future drug development and translational research.

• WEHI-539: Applied Workflows for Selective BCL-XL Inhibition

  2026-04-22

  WEHI-539 empowers apoptosis research with unprecedented selectivity for BCL-XL, enabling targeted dissection of survival pathways in cancer and stem cell models. This guide translates bench-proven protocols and troubleshooting insights into actionable steps for maximizing data quality and reproducibility with this benchmark inhibitor.

• Acute and Chronic Toxicity of Sulfamonomethoxine in Aquatic

  2026-04-21

  This study systematically quantified the acute and chronic toxicity of the veterinary sulfonamide antibiotic sulfamonomethoxine (SMM) in five aquatic organisms across multiple trophic levels. The findings reveal marked sensitivity differences among species, highlighting microalgae as particularly vulnerable and emphasizing the importance of monitoring SMM residues in aquaculture effluents.

• Necrosulfonamide: Precision MLKL Inhibition in Necroptosis A

  2026-04-21

  Necrosulfonamide (NSA) offers unmatched selectivity for MLKL in necroptosis assays, enabling reproducible dissection of cell death pathways in cancer and neurodegenerative models. Discover how NSA, supplied by APExBIO, translates advanced mechanistic insights into reliable, data-driven workflows.

• Entecavir (BMS200475): Mechanistic Precision in HBV Inhibiti

  2026-04-20

  Entecavir (BMS200475) is a potent, selective inhibitor of HBV DNA polymerase, effective in chronic hepatitis B infection therapy. This article details its molecular action, clinical benchmarks, and protocol parameters, referencing APExBIO's BA1816 product and current peer-reviewed evidence.

• IWR-1-endo (SKU B2306): Reliable Wnt Signaling Inhibition in

  2026-04-20

  This article addresses key laboratory challenges in cell viability and proliferation assays where Wnt/β-catenin pathway modulation is critical. Scenario-driven Q&A blocks demonstrate how IWR-1-endo (SKU B2306) offers reproducible, data-backed solutions for colorectal cancer research and stem cell studies, supporting rigorous experimental outcomes.

450 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page